HBP08 peptide

HBP08 peptide

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-GYHYERWIH-OH

H-Gly-Tyr-His-Tyr-Glu-Arg-Trp-Ile-His-OH

9

95.56%

C₆₀H₇₇N₁₇O₁₄

1260.38

Synthetic

Powder

HBP08 is a selective inhibitor of the CXCL12/HMGB1 interaction, which binds to HMGB1 (high mobility group box1) with a Kd of 0.8 µM. HMGB1 is a nonhistone nuclear protein, which acts as a DNA chaperone, contributing to gene transcription and DNA repair, and is released under stress conditions when it forms a heterocomplex with CXCL12. This heterocomplex acts on the chemokine receptor CXCR4, enhancing cell migration, and in some pathological conditions, exacerbating the immune response. HBP08 disruption of this heterocomplex can diminish excessive cell influx at inflammatory sites.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Sgrignani et al (2021) Systematic Development of Peptide Inhibitors Targeting the CXCL12/HMGB1 Interaction. J Med Chem. 64(18) 13439 PMID: 34510899

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.